Search for: "DOW PHARMACEUTICAL SCIENCES, INC."
Results 41 - 60
of 131
Sorted by Relevance
|
Sort by Date
12 Jun 2023, 1:09 pm
In Matrixx Initiatives, Inc. v. [read post]
7 Apr 2011, 1:16 pm
Merrell–Dow Pharmaceuticals, Inc., 523 A.2d 374, 376-79 (Pa. [read post]
5 Jan 2019, 12:15 pm
Merrell Dow Pharmaceuticals, Inc., U.S. [read post]
5 May 2013, 12:15 pm
Merrell Dow Pharmaceuticals, Inc. [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23 requirements. [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23 requirements. [read post]
7 Feb 2009, 10:24 pm
Merrell Dow Pharmaceuticals Inc., 509 U.S. 579 (1993); see also Weisgram v. [read post]
20 Dec 2017, 12:00 am
Merrell Dow Pharmaceuticals, Inc. [read post]
23 May 2008, 10:17 pm
Philip Morris USA, Inc., 142 P.3d 1079 (Or. [read post]
24 Aug 2010, 11:34 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in which the Court instructed district courts to function as gatekeepers and permit only reliable and relevant expert testimony to be presented to the jury. [read post]
30 Oct 2007, 11:28 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), to challenge the reliability of that testimony. [read post]
11 Mar 2013, 8:30 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, has solidified that trend. [read post]
16 Feb 2013, 7:23 am
Merrell Dow Pharmaceuticals, Inc., 509, U.S. 579 (1993). [read post]
12 Nov 2014, 8:01 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 599 (1993) (Rehnquist, C.J., concurring in part and dissenting in part) (‘‘the various briefs filed in this case … deal with definitions of scientific knowledge, scientific method, scientific validity, and peer review—in short, matters far afield from the expertise of judges’’); Marconi Wireless Telegraph Co. of America v. [read post]
7 Jun 2019, 7:39 am
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
12 May 2015, 3:30 pm
Steel Corp. 90271J598 UBS Trigger Phoenix Autocallable Optimization Securities linked to United Rentals, Inc. 90271J523 UBS Trigger Phoenix Autocallable Optimization Securities linked to MGM Resorts International 90271J556 UBS Trigger Phoenix Autocallable Optimization Securities linked to Market Vectors Gold Miners ETF 90271J531 UBS Trigger Phoenix Autocallable Optimization Securities linked to Gilead Sciences Inc. 90271J549 UBS Trigger Phoenix Autocallable Optimization… [read post]
4 Mar 2012, 9:02 am
Merrill Dow Pharmaceuticals, Inc., 874 F.2d 307, 311-12 (5th Cir. 1989)(“Fortunately, we do not have to resolve any of the above questions [as to bias and confounding], since the studies presented to us incorporate the possibility of these factors by the use of a confidence interval. [read post]
